Emerging Markets Sanofi's "Most Important" Segment; Merck Looks To "Win" China: Emerging Markets Earnings Round Up (Part 1)
This article was originally published in PharmAsia News
Executive Summary
Emerging markets continue to figure prominently in Big Pharma strategies for commanding growth, with China being the top priority. For Sanofi SA, more than one-third of its global sales now hail from EMs. Merck invested more than $100 million in EMs in Q2 while it announced it will cut back on its sales force in developed markets.
You may also be interested in...
Sanofi’s Message On Emerging Markets? Catch Us If You Can
Three years ago Sanofi didn’t know it was number one in emerging markets. Now the French pharma can’t talk enough about emerging markets – so what happened?
Merck's $800 Million Investment In Singapore Aims To Produce Returns Elsewhere
SINGAPORE - Merck & Co. Inc. has committed to manufacturing and research investments in Singapore totaling more than $800 million to meet the ever increasing demand in nearby emerging markets
Merck's $800 Million Investment In Singapore Aims To Produce Returns Elsewhere
SINGAPORE - Merck & Co. Inc. has committed to manufacturing and research investments in Singapore totaling more than $800 million to meet the ever increasing demand in nearby emerging markets